Tags

Type your tag names separated by a space and hit enter

Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus.
Expert Opin Pharmacother 2009; 10(12):1875-82EO

Abstract

AIM

The aim of the present study was to compare the effects of simvastatin and L-carnitine coadministration versus simvastatin monotherapy on lipid profile, lipoprotein(a) (Lp(a)) and apoprotein(a) (Apo(a)) levels in type II diabetic patients.

PATIENTS/METHODS

In this double-blind, randomized clinical trial, 75 patients were assigned to one of two treatment groups for 4 months. Group A received simvastatin monotherapy; group B received L-carnitine and simvastatin. The following variables were assessed at baseline, after washout and at 1, 2, 3 and 4 months of treatment: body mass index, fasting plasma glucose, glycated hemoglobin, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, Apolipoprotein A1, Apo B, lipoprotein(a) and apoprotein(a).

RESULTS

At the end of treatment in the carnitine and simvastatin combined group compared with the simvastatin alone group, we observed a significant decrease in glycemia (p < 0.001), triglycerides (p < 0.001), Apo B (p < 0.05), Lp(a) (p < 0.05), apo(a) (p < 0.05), while HDL significantly increased (p < 0.05).

CONCLUSIONS

The coadministration of carnitine and simvastatin resulted in a significant reduction in Lp(a) and apo(a) and may represent a new therapeutic option in reducing plasma Lp(a) levels, LDL cholesterol and Apo B100.

Authors+Show Affiliations

University of Catania, Department of Biological Chemistry, Medical Chemistry and Molecular Biology, Viale A. Doria 6, 95125 Catania, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19618992

Citation

Galvano, Fabio, et al. "Effects of Simvastatin and Carnitine Versus Simvastatin On Lipoprotein(a) and Apoprotein(a) in Type 2 Diabetes Mellitus." Expert Opinion On Pharmacotherapy, vol. 10, no. 12, 2009, pp. 1875-82.
Galvano F, Li Volti G, Malaguarnera M, et al. Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert Opin Pharmacother. 2009;10(12):1875-82.
Galvano, F., Li Volti, G., Malaguarnera, M., Avitabile, T., Antic, T., Vacante, M., & Malaguarnera, M. (2009). Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert Opinion On Pharmacotherapy, 10(12), pp. 1875-82. doi:10.1517/14656560903081745.
Galvano F, et al. Effects of Simvastatin and Carnitine Versus Simvastatin On Lipoprotein(a) and Apoprotein(a) in Type 2 Diabetes Mellitus. Expert Opin Pharmacother. 2009;10(12):1875-82. PubMed PMID: 19618992.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. AU - Galvano,Fabio, AU - Li Volti,Giovanni, AU - Malaguarnera,Michele, AU - Avitabile,Teresio, AU - Antic,Tijana, AU - Vacante,Marco, AU - Malaguarnera,Mariano, PY - 2009/7/22/entrez PY - 2009/7/22/pubmed PY - 2009/10/1/medline SP - 1875 EP - 82 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 10 IS - 12 N2 - AIM: The aim of the present study was to compare the effects of simvastatin and L-carnitine coadministration versus simvastatin monotherapy on lipid profile, lipoprotein(a) (Lp(a)) and apoprotein(a) (Apo(a)) levels in type II diabetic patients. PATIENTS/METHODS: In this double-blind, randomized clinical trial, 75 patients were assigned to one of two treatment groups for 4 months. Group A received simvastatin monotherapy; group B received L-carnitine and simvastatin. The following variables were assessed at baseline, after washout and at 1, 2, 3 and 4 months of treatment: body mass index, fasting plasma glucose, glycated hemoglobin, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, Apolipoprotein A1, Apo B, lipoprotein(a) and apoprotein(a). RESULTS: At the end of treatment in the carnitine and simvastatin combined group compared with the simvastatin alone group, we observed a significant decrease in glycemia (p < 0.001), triglycerides (p < 0.001), Apo B (p < 0.05), Lp(a) (p < 0.05), apo(a) (p < 0.05), while HDL significantly increased (p < 0.05). CONCLUSIONS: The coadministration of carnitine and simvastatin resulted in a significant reduction in Lp(a) and apo(a) and may represent a new therapeutic option in reducing plasma Lp(a) levels, LDL cholesterol and Apo B100. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/19618992/Effects_of_simvastatin_and_carnitine_versus_simvastatin_on_lipoprotein_a__and_apoprotein_a__in_type_2_diabetes_mellitus_ L2 - http://www.tandfonline.com/doi/full/10.1517/14656560903081745 DB - PRIME DP - Unbound Medicine ER -